RecruitingNCT05618080
LGMD R1 Natural History Study
GRASP-01-003: Trial Readiness and Endpoint Assessment in LGMD R1
Sponsor
Virginia Commonwealth University
Enrollment
100 participants
Start Date
Jan 31, 2024
Study Type
OBSERVATIONAL
Conditions
Summary
This is a 24-month, observational study of 100 participants with Limb Girdle Muscular Dystrophy type R1, also known as CAPN3.
Eligibility
Min Age: 12 YearsMax Age: 50 Years
Plain Language Summary
Simplified for easier understanding
This natural history study follows people with Limb-Girdle Muscular Dystrophy type R1 (LGMD R1), a rare genetic muscle disease caused by mutations in the CAPN3 gene. It causes progressive weakness in the shoulder and hip muscles. The study uses MRI, muscle strength testing, and other assessments over time to track how the disease progresses, which will help researchers design future treatments and clinical trials.
You may be eligible if:
- You are between 12 and 50 years old
- You have confirmed LGMD R1 with genetic testing (homozygous or compound heterozygous mutations in CAPN3)
- You have muscle weakness consistent with LGMD R1
- You can walk 10 meters without assistive devices (ankle-foot orthotics are okay)
- You are able to provide your own informed consent (adults must consent themselves)
You may NOT be eligible if:
- You have a contraindication to MRI (e.g., metal implants, severe claustrophobia)
- You are unable to walk 10 meters independently
- You are pregnant
- You have a dominant (not recessive) form of CAPN3 mutation (LGMD D4)
- You have another illness that would affect the test results
Talk to your doctor to see if this trial is right for you.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(12)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05618080
Related Trials
A Study to Evaluate the Safety of AB-1003 (Previously LION-101) in Subjects With Genetic Confirmation of LGMD2I/R9 (Part1)
NCT052304596 locations
Long-Term Development of Muscular Dystrophy Outcome Assessments
NCT059896201 location
MRI-phenotyping of Patients With Pathogenic Anoctamin 5 Variants
NCT051027991 location
Rehabilitation in Muscular Dystrophies From the Hospital Facility to the Home: Pilot Project [RIMUDI]
NCT063782031 location
Molecular Analysis of Patients With Neuromuscular Disease
NCT003901041 location